Molecular Partners AG (MLLCF) Gets a Hold from J.P. Morgan

Detailed price information for Molecular Partners Ag ADR (MOLN-Q) from The Globe and Mail including charting and trades.

Morgan Stanley: Moat—On-Site Research of CATL

The production line independently developed by CATL features a high degree of complexity and intelligence, combined with advanced materials science. This should continue to set high entry barriers, ...
Seeking Alpha

4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

To this session of the Morgan Stanley Global Healthcare Conference. I'm excited to welcome the team from 4D Molecular Therapeutics. Let me just get through a quick disclosure before we get started.
WRIC

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025 Mesothelin named as second target in Radio-DARPin pipeline, program to be co-developed with ...

Bristol-Myers Squibb (BMY): Assessing Valuation After New Pipeline Updates and Growth Strategy Reveal

If you have been weighing what to do with Bristol-Myers Squibb (BMY), recent company updates might make you pause and ...

Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Terns Pharmaceuticals, Inc. ( NASDAQ: TERN) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:00 AM EDT ...